Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(3):560–567. doi: 10.1054/bjoc.1999.0964

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

A Paradiso 1, G Simone 2, S Petroni 2, B Leone 4, C Vallejo 4, J Lacava 4, A Romero 4, M Machiavelli 4, M De Lena 3, C J Allegra 5, P G Johnston 6
PMCID: PMC2363320  PMID: 10682666

Abstract

The purpose of this work was to analyse the ability of p53 and thymidilate synthase (TS) primary tumour expression to retrospectively predict clinical response to chemotherapy and long-term prognosis in patients with advanced colorectal cancers homogeneously treated by methotrexate (MTX)-modulated–5-fluorouracil (5-FU-FA). A total of 108 advanced colorectal cancer patients entered the present retrospective study. Immunohistochemical p53 (pAb 1801 mAb) and TS (TS106 mAb) expression on formalin-fixed paraffin-embedded primary tumour specimens was related to probability of clinical response to chemotherapy, time to progression and overall survival. p53 was expressed in 53/108 (49%) tumours, while 54/108 (50%) showed TS immunostaining. No relationship was demonstrated between p53 positivity and clinical response to chemotherapy (objective response (OR): 20% vs 23%, in p53+ and p53– cases respectively) or overall survival. Percent of OR was significantly higher in TS-negative with respect to TS-positive tumours (30% vs 15% respectively;P< 0.04); simultaneous analysis of TS and p53 indicated 7% OR for p53-positive/TS-positive tumours vs 46% for p53-positive/TS-negative tumours (P< 0.03). Logistic regression analysis confirmed a significant association between TS tumour status and clinical response to chemotherapy (hazard ratio (HR): 2.91; 95% confidence interval (CI) 8.34–1.01; two-sided P< 0.05). A multivariate analysis of overall survival showed that only a small number of metastatic sites was statistically relevant (HR 1.89; 95% CI 2.85–1.26; two-sided P< 0.03). Our study suggests that immunohistochemical expression of p53 and TS could assist the clinician in predicting response of colorectal cancer patients to modulated MTX-5-FU therapy. © 2000 Cancer Research Campaign

Keywords: TS, p53, predictive factor, prognosis, colorectal cancer

Full Text

The Full Text of this article is available as a PDF (151.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abulrahi H. A., Bohlega E. A., Fontaine R. E., al-Seghayer S. M., al-Ruwais A. A. Plasmodium falciparum malaria transmitted in hospital through heparin locks. Lancet. 1997 Jan 4;349(9044):23–25. doi: 10.1016/s0140-6736(96)03508-8. [DOI] [PubMed] [Google Scholar]
  2. Belluco C., Guillem J. G., Kemeny N., Huang Y., Klimstra D., Berger M. F., Cohen A. M. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol. 1996 Oct;14(10):2696–2701. doi: 10.1200/JCO.1996.14.10.2696. [DOI] [PubMed] [Google Scholar]
  3. Bhatavdekar J. M., Patel D. D., Ghosh N., Chikhlikar P. R., Trivedi T. I., Suthar T. P., Doctor S. S., Shah N. G., Balar D. B. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum. 1997 Jul;40(7):785–790. doi: 10.1007/BF02055433. [DOI] [PubMed] [Google Scholar]
  4. Bosari S., Viale G., Bossi P., Maggioni M., Coggi G., Murray J. J., Lee A. K. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst. 1994 May 4;86(9):681–687. doi: 10.1093/jnci/86.9.681. [DOI] [PubMed] [Google Scholar]
  5. Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992 Jan 24;255(5043):459–462. doi: 10.1126/science.1346476. [DOI] [PubMed] [Google Scholar]
  6. Chu E., Drake J. C., Koeller D. M., Zinn S., Jamis-Dow C. A., Yeh G. C., Allegra C. J. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol. 1991 Feb;39(2):136–143. [PubMed] [Google Scholar]
  7. Chu E., Koeller D. M., Casey J. L., Drake J. C., Chabner B. A., Elwood P. C., Zinn S., Allegra C. J. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8977–8981. doi: 10.1073/pnas.88.20.8977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cook A., Milner J. Evidence for allosteric variants of wild-type p53, a tumour suppressor protein. Br J Cancer. 1990 Apr;61(4):548–552. doi: 10.1038/bjc.1990.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Edler D., Blomgren H., Allegra C. J., Johnston P. G., Lagerstedt U., Magnusson I., Ragnhammar P. Immunohistochemical determination of thymidylate synthase in colorectal cancer--methodological studies. Eur J Cancer. 1997 Nov;33(13):2278–2281. doi: 10.1016/s0959-8049(97)00306-7. [DOI] [PubMed] [Google Scholar]
  10. Findlay M. P., Cunningham D., Morgan G., Clinton S., Hardcastle A., Aherne G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer. 1997;75(6):903–909. doi: 10.1038/bjc.1997.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  12. Hermeking H., Eick D. Mediation of c-Myc-induced apoptosis by p53. Science. 1994 Sep 30;265(5181):2091–2093. doi: 10.1126/science.8091232. [DOI] [PubMed] [Google Scholar]
  13. Isacoff W. H., Borud K. Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. World J Surg. 1997 Sep;21(7):748–762. doi: 10.1007/s002689900301. [DOI] [PubMed] [Google Scholar]
  14. Johnston P. G., Fisher E. R., Rockette H. E., Fisher B., Wolmark N., Drake J. C., Chabner B. A., Allegra C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994 Dec;12(12):2640–2647. doi: 10.1200/JCO.1994.12.12.2640. [DOI] [PubMed] [Google Scholar]
  15. Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., Danenberg P. V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995 Apr 1;55(7):1407–1412. [PubMed] [Google Scholar]
  16. Johnston P. G., Liang C. M., Henry S., Chabner B. A., Allegra C. J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res. 1991 Dec 15;51(24):6668–6676. [PubMed] [Google Scholar]
  17. Johnston P. G., Mick R., Recant W., Behan K. A., Dolan M. E., Ratain M. J., Beckmann E., Weichselbaum R. R., Allegra C. J., Vokes E. E. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19;89(4):308–313. doi: 10.1093/jnci/89.4.308. [DOI] [PubMed] [Google Scholar]
  18. Kornmann M., Link K. H., Lenz H. J., Pillasch J., Metzger R., Butzer U., Leder G. H., Weindel M., Safi F., Danenberg K. D. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett. 1997 Sep 16;118(1):29–35. doi: 10.1016/s0304-3835(97)00220-6. [DOI] [PubMed] [Google Scholar]
  19. Larsson P. A., Carlsson G., Gustavsson B., Spears C. P. Thymidylate synthase in advanced gastrointestinal and breast cancers. Acta Oncol. 1996;35(4):469–472. doi: 10.3109/02841869609109924. [DOI] [PubMed] [Google Scholar]
  20. Lee Y., Chen Y., Chang L. S., Johnson L. F. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res. 1997 Aug 1;234(2):270–276. doi: 10.1006/excr.1997.3605. [DOI] [PubMed] [Google Scholar]
  21. Leichman C. G., Lenz H. J., Leichman L., Danenberg K., Baranda J., Groshen S., Boswell W., Metzger R., Tan M., Danenberg P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997 Oct;15(10):3223–3229. doi: 10.1200/JCO.1997.15.10.3223. [DOI] [PubMed] [Google Scholar]
  22. Lenz H. J., Hayashi K., Salonga D., Danenberg K. D., Danenberg P. V., Metzger R., Banerjee D., Bertino J. R., Groshen S., Leichman L. P. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res. 1998 May;4(5):1243–1250. [PubMed] [Google Scholar]
  23. Lowe S. W., Bodis S., McClatchey A., Remington L., Ruley H. E., Fisher D. E., Housman D. E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994 Nov 4;266(5186):807–810. doi: 10.1126/science.7973635. [DOI] [PubMed] [Google Scholar]
  24. Machiavelli M., Leone B. A., Romero A., Rabinovich M. G., Vallejo C. T., Bianco A., Pérez J. E., Rodríguez R., Cuevas M. A., Alvarez L. A. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. Am J Clin Oncol. 1991 Jun;14(3):211–217. [PubMed] [Google Scholar]
  25. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer. 1997 Oct 1;80(7):1179–1187. doi: 10.1002/(sici)1097-0142(19971001)80:7<1179::aid-cncr1>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  26. Manne U., Myers R. B., Moron C., Poczatek R. B., Dillard S., Weiss H., Brown D., Srivastava S., Grizzle W. E. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer. 1997 Jun 20;74(3):346–358. doi: 10.1002/(sici)1097-0215(19970620)74:3<346::aid-ijc19>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  27. Merchant A. K., Loney T. L., Maybaum J. Expression of wild-type p53 stimulates an increase in both Bax and Bcl-xL protein content in HT29 cells. Oncogene. 1996 Dec 19;13(12):2631–2637. [PubMed] [Google Scholar]
  28. Mueller H., Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res. 1996 Nov-Dec;16(6B):3845–3848. [PubMed] [Google Scholar]
  29. Navalgund L. G., Rossana C., Muench A. J., Johnson L. F. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem. 1980 Aug 10;255(15):7386–7390. [PubMed] [Google Scholar]
  30. Paradiso A., Rabinovich M., Vallejo C., Machiavelli M., Romero A., Perez J., Lacava J., Cuevas M. A., Rodriquez R., Leone B. p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer. 1996 Dec 20;69(6):437–441. doi: 10.1002/(SICI)1097-0215(19961220)69:6<437::AID-IJC2>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  31. Pestalozzi B. C., McGinn C. J., Kinsella T. J., Drake J. C., Glennon M. C., Allegra C. J., Johnston P. G. Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer. 1995 Jun;71(6):1151–1157. doi: 10.1038/bjc.1995.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pestalozzi B. C., Peterson H. F., Gelber R. D., Goldhirsch A., Gusterson B. A., Trihia H., Lindtner J., Cortés-Funes H., Simmoncini E., Byrne M. J. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol. 1997 May;15(5):1923–1931. doi: 10.1200/JCO.1997.15.5.1923. [DOI] [PubMed] [Google Scholar]
  33. Peters G. J., van der Wilt C. L., van Groeningen C. J., Smid K., Meijer S., Pinedo H. M. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol. 1994 Oct;12(10):2035–2042. doi: 10.1200/JCO.1994.12.10.2035. [DOI] [PubMed] [Google Scholar]
  34. Peters G. J., van der Wilt C. L., van Triest B., Codacci-Pisanelli G., Johnston P. G., van Groeningen C. J., Pinedo H. M. Thymidylate synthase and drug resistance. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1299–1305. doi: 10.1016/0959-8049(95)00172-f. [DOI] [PubMed] [Google Scholar]
  35. Simes R. J., Zelen M. Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer. J Clin Oncol. 1985 Oct;3(10):1418–1431. doi: 10.1200/JCO.1985.3.10.1418. [DOI] [PubMed] [Google Scholar]
  36. Slebos R. J., Baas I. O., Clement M., Polak M., Mulder J. W., van den Berg F. M., Hamilton S. R., Offerhaus G. J. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer. 1996 Jul;74(2):165–171. doi: 10.1038/bjc.1996.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Smith D. R., Ji C. Y., Goh H. S. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer. 1996 Jul;74(2):216–223. doi: 10.1038/bjc.1996.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Spears C. P. Clinical resistance to antimetabolites. Hematol Oncol Clin North Am. 1995 Apr;9(2):397–413. [PubMed] [Google Scholar]
  39. Spears C. P., Shahinian A. H., Moran R. G., Heidelberger C., Corbett T. H. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res. 1982 Feb;42(2):450–456. [PubMed] [Google Scholar]
  40. Yang B., Eshleman J. R., Berger N. A., Markowitz S. D. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res. 1996 Oct;2(10):1649–1657. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES